MANGALAM · Mangalam Drugs And Organics Ltd · Biotechnology & Drugs
MANGALAM · Mangalam Drugs And Organics Ltd · Biotechnology & Drugs
As of 05 Nov close
52-week range
55.2% below 52-week high
52-week range: as of 05 Nov 2026 close.
Price chartDaily closes on the stock page.
Weighted combination of 8 measured readings. Not a probability, a rating or a forecast.
Full signal detail →Fundamentals as of 16 Oct 2026
Revenue (latest Q)
₹57 Cr
Revenue YoY
PAT YoY
+44.6%
Operating margin
Revenue, last 5 quarters
Source: Yahoo Finance, as of 30 Jun 2026
P/E (TTM)
P/B
0.5
P/S (TTM)
Not available from data source
Sector P/E
Not available from data source
Dividend yield
Not available from data source
Source: Yahoo Finance, as of 29 Oct 2026
| Company | P/E | P/B | Net margin | ROE | D/E | Div. yield |
|---|---|---|---|---|---|---|
| MANGALAM (this stock) | Not meaningful (earnings negative over the last 12 months) | 0.5 | -16.5% | -43.1% | 1.09 | Not available from data source |
| Sun Pharmaceutical Industries | 36.6 | 5.3 | Not available from data source | Not available from data source | Not available from data source | Not available from data source |
| Divi's Laboratories * | 59.7 | 14.5 | +26.1% | +17.4% | 0 | +0.3% |
| Torrent Pharmaceuticals | 75.8 | 20 | Not available from data source | Not available from data source | Not available from data source | Not available from data source |
* Net margin, ROE, D/E and dividend yield for these companies come from RedixFi fundamentals; the data vendor had no values for them.
Promoter
stable
FII
falling 1q
MF
Not available from data source
Insider trades
No insider trades in the last 12 months.
Bulk/block deals
No bulk/block deals in the last 12 months.
News timeline
No related news.
Concalls & investor presentations
AI-generatedNo concall transcripts or investor presentations recorded yet.
AI Summary of Annual Report
AI-generatedMangalam Drugs & Organics Limited's 53rd Annual Report for FY2025-26 highlights a challenging year marked by management's stated 26.90% decline in revenue and significant operational losses, primarily due to external factors affecting global pharmaceutical procurement. The company's reliance on international tenders for anti-malarial and tropical disease APIs has been impacted by reduced donor funding and geopolitical issues. Despite these challenges, the company emphasizes its diverse API portfolio and backward integration strategies. The report also outlines plans for enhancing manufacturing technology, sustainability initiatives, and R&D investments to drive long-term growth. Additionally, the company faces financial and operational risks, including loan defaults and compliance issues with regulatory requirements.
- The company's revenue declined significantly due to external factors impacting global pharmaceutical procurement.
- Focus on backward integration and diversification of API portfolio to enhance supply chain resilience.
- Commitment to sustainability and green chemistry principles as part of long-term growth strategy.
- Plans to strengthen R&D infrastructure for complex generic products and advanced synthetic chemistry.
- Strategic initiatives to improve manufacturing technology and operational flexibility.
Key takeaway: Mangalam Drugs & Organics Limited faces significant challenges due to external factors affecting global pharmaceutical procurement, but is focusing on strategic initiatives to enhance supply chain resilience, sustainability, and R&D to drive long-term growth.
The following annual report excerpts provide qualitative strategic context. Do not treat any specific financial figures in these excerpts as authoritative — they may be incorrectly labeled due to PDF table extraction limitations. For precise financial data, refer to the structured fundamentals data above.
Governance disclosures
AI-generatedNeeds attention
Regulatory Action (2 items); Default / Covenant Breach (1 item)
Items of these kinds are disclosed in the filings. This is a count of disclosed items. It is not a finding about the company and its cause has not been independently established.
Regulatory Action
2 occurrencesRecent (last 12 months)
Mangalam Drugs & Organics Limited could not comply with SEBI (LODR) requirements for Independent Directors and Audit Committee composition during January 16, 2026 to March 31, 2026.
Earlier (1-3 years ago)
The company failed to comply with SEBI (Prohibition of Insider Trading) Regulations, 2015, during the period under review, but has since ensured compliance from December 2024.
Default / Covenant Breach
1 occurrenceRecent (last 12 months)
The company defaulted in repayment of borrowings during the year, as disclosed in note no. 14 of the standalone financial statements.
Routine disclosures
Internal Control Weakness
1 occurrenceRecent (last 12 months)
The auditor mentions that a misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
Contingent Liability
2 occurrencesRecent (last 12 months)
Mangalam Drugs & Organics Limited had a secured loan of Rs.13.64 Lakhs with Ugro Capital Limited, which was delayed in repayment from November 25 to March 26, but the delay has been remedied as of March 31, 2026.
Earlier (1-3 years ago)
The company has secured working capital facilities from State Bank of India, Bank of Baroda, and Bank of Maharashtra against a first and second pari passu charge on its Property, Plant & Equipment and current assets, respectively, and these loans are guaranteed by the Managing Director's personal guarantee.
Related-Party Transaction
2 occurrencesRecent (last 12 months)
The company has disclosed transactions with related parties, including commission paid, purchase and sale of goods, and rent received and paid with entities like Shri JB Pharma Private Limited, Mangalam Laboratories Private Limited, and Raga Organics Private Limited during the year ended March 31, 2026.
Earlier (1-3 years ago)
The company has approved material related party transactions, as per the resolution passed at the AGM, involving related parties as defined under the Companies Act and SEBI regulations.
Management & Board Governance
1 occurrenceRecent (last 12 months)
Shri Rukmesh Dhandhania resigned as an Independent Director w.e.f. 16th January, 2026, leading to Shri Praveen Saxena's appointment as a member of the Audit Committee w.e.f. 6th February, 2026.
Promoter Share Pledge
1 occurrenceRecent (last 12 months)
2.18% of promoter holding pledged (quarter 2026-Q3 as of 2026-07-18).